Skip to main content
Retour
DNLI logo

Denali Therapeutics Inc.

Qualité des données : 100%
DNLI
NASDAQ Healthcare Biotechnology
22,47 €
▲ 1,50 € (7,15%)
Cap. Boursière : 3,56B
Fourchette du Jour
21,27 € 23,46 €
Fourchette 52 Semaines
10,57 € 23,77 €
Volume
5 398 763
Moyenne 50J / 200J
20,15 € / 16,67 €
Clôture Précédente
20,97 €

Quick Summary

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (631 pairs)

Métrique Action Médiane du Secteur
P/E -7,0 0,2
P/B 3,5 3,0
ROE % -45,7 3,6
Net Margin % 3,8
Rev Growth 5Y % 9,7
D/E 0,0 0,2

Objectif de Cours des Analystes

Hold
34,40 € +53.1%
Low: 25,00 € High: 40,00 €
BPA Prévisionnel
-2,72 €
CA Est.
50,59M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 1,83 €
-0,15 € – 5,02 €
1,07B 5
FY2029 0,25 €
-0,02 € – 0,70 €
698,58M 11
FY2028 -0,69 €
-2,17 € – 1,30 €
506,19M 13

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-26 -0,74 € -0,73 € +0,9%
2025-11-06 -0,76 € -0,74 € +2,6%
2025-08-11 -0,74 € -0,72 € +2,7%
2025-05-06 -0,71 € -0,78 € -9,9%
2025-02-27 -0,75 € -0,67 € +10,7%
2024-11-06 -0,60 € -0,63 € -5,0%
2024-08-01 -0,68 € -0,59 € +13,2%
2024-05-07 -0,67 € -0,68 € -1,5%

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Points Clés

Debt/Equity of 0,04 — conservative balance sheet
Negative free cash flow of -422,10M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-45,69%
ROIC-39,44%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
0,04
Current Ratio9,16
Interest Coverage0,00

Valorisation

P/E Ratio
-6,95
Forward P/EN/A
P/B Ratio3,52
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -512,54M
ROE -45,69% ROA -44,77%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -422,10M
ROIC -39,44% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,04 Current Ratio 9,16
Interest Coverage 0,00
Dividends
Dividend Yield 0,00% Payout Ratio 0,00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -6,95 Forward P/E N/A
P/B Ratio 3,52 P/S Ratio N/A
PEG Ratio -0,36 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 70,44 Fwd Earnings Yield N/A
FCF Yield -11,85%
Market Cap 3,56B Enterprise Value 3,40B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 0,0 330,53M 108,46M 48,66M
Net Income -512,54M -422,77M -145,22M -325,99M -290,58M
EPS (Diluted) -2,97 -2,57 -1,06 -2,60 -2,39
Gross Profit -11,18M 0,0 330,53M 108,46M 48,66M
Operating Income -555,34M -487,34M -196,70M -340,74M -295,75M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,14B 1,37B 1,15B 1,46B 1,40B
Total Liabilities 131,09M 144,50M 122,96M 417,81M 441,87M
Shareholders' Equity 1,01B 1,23B 1,03B 1,04B 962,29M
Total Debt 42,29M 48,71M 52,24M 60,35M 64,01M
Cash & Equivalents 205,33M 174,96M 127,11M 218,04M 293,48M
Current Assets 900,66M 864,44M 1,06B 1,37B 897,23M
Current Liabilities 98,35M 102,21M 77,98M 363,92M 378,25M